TY - JOUR

T1 - Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

AU - Donnelly, J Peter

AU - Chen, Sharon C

AU - Kauffman, Carol A

AU - Steinbach, William J

AU - Baddley, John W

AU - Verweij, Paul E

AU - Clancy, Cornelius J

AU - Wingard, John R

AU - Lockhart, Shawn R

AU - Groll, Andreas H

AU - Sorrell, Tania C

AU - Bassetti, Matteo

AU - Akan, Hamdi

AU - Alexander, Barbara D

AU - Andes, David

AU - Azoulay, Elie

AU - Bialek, Ralf

AU - Bradsher, Robert W

AU - Bretagne, Stephane

AU - Calandra, Thierry

AU - Caliendo, Angela M

AU - Castagnola, Elio

AU - Cruciani, Mario

AU - Cuenca-Estrella, Manuel

AU - Decker, Catherine F

AU - Desai, Sujal R

AU - Fisher, Brian

AU - Harrison, Thomas

AU - Heussel, Claus Peter

AU - Jensen, Henrik E

AU - Kibbler, Christopher C

AU - Kontoyiannis, Dimitrios P

AU - Kullberg, Bart-Jan

AU - Lagrou, Katrien

AU - Lamoth, Frédéric

AU - Lehrnbecher, Thomas

AU - Loeffler, Jurgen

AU - Lortholary, Olivier

AU - Maertens, Johan

AU - Marchetti, Oscar

AU - Marr, Kieren A

AU - Masur, Henry

AU - Meis, Jacques F

AU - Morrisey, C Orla

AU - Nucci, Marcio

AU - Ostrosky-Zeichner, Luis

AU - Pagano, Livio

AU - Patterson, Thomas F

AU - Perfect, John R

AU - Racil, Zdenek

AU - Roilides, Emmanuel

AU - Ruhnke, Marcus

AU - Prokop, Cornelia Schaefer

AU - Shoham, Shmuel

AU - Slavin, Monica A

AU - Stevens, David A

AU - Thompson, George R

AU - Vazquez, Jose A

AU - Viscoli, Claudio

AU - Walsh, Thomas J

AU - Warris, Adilia

AU - Wheat, L Joseph

AU - White, P Lewis

AU - Zaoutis, Theoklis E

AU - Pappas, Peter G

N1 - © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

AB - BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

U2 - 10.1093/cid/ciz1008

DO - 10.1093/cid/ciz1008

M3 - Journal article

C2 - 31802125

VL - 71

SP - 1367

EP - 1376

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -